NIH $ frozen amid conflict probe

An Emory University psychiatrist under investigation by a Senate committee for allegedly failing to disclose more than a million dollars in pharmaceutical company pay has stepped down as principal investigator on a $9.3 million National Institutes of Health research grant. The researcher, Charles Nemeroff, is the linkurl:second;http://www.the-scientist.com/blog/display/54935/ scientist who has recently stepped down from an NIH grant amid Senate scrutiny of undisclosed conflicts of interest. Ac

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
An Emory University psychiatrist under investigation by a Senate committee for allegedly failing to disclose more than a million dollars in pharmaceutical company pay has stepped down as principal investigator on a $9.3 million National Institutes of Health research grant. The researcher, Charles Nemeroff, is the linkurl:second;http://www.the-scientist.com/blog/display/54935/ scientist who has recently stepped down from an NIH grant amid Senate scrutiny of undisclosed conflicts of interest. According to Ron Sauder, an Emory spokesperson interviewed by the linkurl:__Atlanta Journal-Constitution__,;http://www.ajc.com/metro/content/metro/dekalb/stories/2008/10/14/nemeroff_emory_funds.html the NIH will withhold the remainder of funding on the five-year grant - which began in July 2006 - "pending resolution of outstanding issues relating to conflict of interest procedures." Nemeroff linkurl:resigned;http://www.the-scientist.com/blog/display/55072/ his chairmanship of Emory's psychiatry department on October 3 as the university launched its own investigation into his apparent failure to disclose industry ties. The NIH is now requiring the university's Office of Sponsored Programs (OSP) and all Emory researchers hoping to secure agency funding to submit and assure detailed records of who is participating on proposed projects and what financial conflicts they may have. "As you may know, the University has been under scrutiny in connection with our business practices for the management of research financial conflict of interest," Emory's vice president for research administration David Wynes wrote in a linkurl:memo;http://www.pharmalot.com/wp-content/uploads/2008/10/emory-coi-1a.jpg to university researchers last week. "It is important to note that, in the future, OSP will non [sic] submit any NIH grant application until disclosures have been received for every Investigator participating in the study." In the memo, Wynes explained that "as of October 8, 2008 the NIH has imposed special award conditions on all awards made to Emory University. The special award conditions will affect both the submission of proposals to the NIH as well as the receipt of funding." (Thanks to the linkurl:__Pharmalot__;http://www.pharmalot.com/2008/10/nih-requires-emory-to-disclose-all-conflicts/ blog for posting a copy of the memo.) Nemeroff was originally accused of linkurl:failing to report payments from drug maker GlaxoSmithKline;http://www.the-scientist.com/blog/display/55072/ by Senate Finance Committee ranking Republican Charles Grassley, who has recently linkurl:investigated;http://www.the-scientist.com/blog/display/55058/ similar apparent indiscretions among other NIH-funded researchers.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies